Indication: Rejection or graft-versus-host disease, autoimmune disease

Indication: This product is suitable for: malignant tumor patients with low immune function caused by radiotherapy and chemotherapy. (1) For patients with chronic hepatitis B over 18 years old. (2) Various primary or secondary T cell deficiency diseases (such as congenital immunodeficiency in children). (3) Certain autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.). (Lupus erythematosus is an autoimmune disease with a slow onset and insidious occurrence. The clinical manifestations are diverse and varied. It is an autoimmune disease involving many systems and organs. Due to the dysfunction of cellular and humoral immune function, a variety of autoantibodies are produced. It can affect the skin, serous membranes, joints, kidneys and central nervous system, etc., and is characterized by autoimmunity. There are multiple autoantibodies in the patient's body, which not only affect humoral immunity, but also cellular immunity, and the complement system also changes. The pathogenesis is mainly due to the formation of immune complexes. The exact cause is unknown. The condition is a process of repeated attacks and remissions.) (4) Various diseases with low cellular immune function. (5) Adjuvant treatment of tumors.

Indication: This product is suitable for: malignant tumor patients with low immune function caused by radiotherapy and chemotherapy. (1) For patients with chronic hepatitis B over 18 years old. (2) Various primary or secondary T cell deficiency diseases (such as congenital immunodeficiency in children). (3) Certain autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.). (Lupus erythematosus is an autoimmune disease with a slow onset and insidious occurrence. The clinical manifestations are diverse and varied. It is an autoimmune disease involving many systems and organs. Due to the dysfunction of cellular and humoral immune function, a variety of autoantibodies are produced. It can affect the skin, serous membranes, joints, kidneys and central nervous system, etc., and is characterized by autoimmunity. There are multiple autoantibodies in the patient's body, which not only affect humoral immunity, but also cellular immunity, and the complement system also changes. The pathogenesis is mainly due to the formation of immune complexes. The exact cause is unknown. The condition is a process of repeated attacks and remissions.) (4) Various diseases with low cellular immune function. (5) Adjuvant treatment of tumors.

Indication: This product is suitable for: malignant tumor patients with low immune function caused by radiotherapy and chemotherapy. (1) For patients with chronic hepatitis B over 18 years old. (2) Various primary or secondary T cell deficiency diseases (such as congenital immunodeficiency in children). (3) Certain autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.). (Lupus erythematosus is an autoimmune disease with a slow onset and insidious occurrence. The clinical manifestations are diverse and varied. It is an autoimmune disease involving many systems and organs. Due to the dysfunction of cellular and humoral immune function, a variety of autoantibodies are produced. It can affect the skin, serous membranes, joints, kidneys and central nervous system, etc., and is characterized by autoimmunity. There are multiple autoantibodies in the patient's body, which not only affect humoral immunity, but also cellular immunity, and the complement system also changes. The pathogenesis is mainly due to the formation of immune complexes. The exact cause is unknown. The condition is a process of repeated attacks and remissions.) (4) Various diseases with low cellular immune function. (5) Adjuvant treatment of tumors.

Indication: 1. Prevent and treat rejection or graft-versus-host reaction of allogeneic organ transplantation or bone marrow transplantation. 2. Autoimmune diseases such as lupus nephritis and refractory nephrotic syndrome that are ineffective after other immunosuppressive agents.

Indication: 1. Confirmed indications (1) Transplantation a. Organ transplantation - prevention of allogeneic transplant rejection, including kidney, liver, heart, lung, combined heart-lung and pancreas transplantation. - Treatment of transplant rejection in patients who have received other immunosuppressants. b. Bone marrow transplantation - prevention of bone marrow transplant rejection. - Prevention and treatment of GVHD. (2) Non-transplant indications The person who diagnoses and prescribes this product should be a physician with experience in the use of immunosuppressants, especially cyclosporine. a. Endogenous uveitis - active non-infectious uveitis of the central or posterior part of the body with a risk of blindness, in which conventional therapy is ineffective or produces unacceptable adverse reactions. - Patients aged 7-70 years with Behcet's uveitis and recurrent retinitis with normal renal function. b. Psoriasis

Indication: 1. Prevent and treat rejection or graft-versus-host reaction of allogeneic organ transplantation or bone marrow transplantation. 2. Treat autoimmune diseases such as lupus nephritis and refractory nephrotic syndrome that have not been effectively treated with other immunosuppressants.

Indication: For chronic hepatitis B patients over 18 years old. Because the thymus begins to atrophy after 18 years old, the cellular immune function is reduced. 2 Various primary or secondary T cell deficiency diseases. 3 Certain autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.). 4 Various diseases with low cellular immune function. 5 Adjuvant treatment of tumors.

Indication: 1 For chronic hepatitis B patients over 18 years old. Because the thymus begins to shrink after 18 years old, the cellular immune function is reduced. 2 Various primary or secondary T cell deficiency diseases. 3 Certain autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.). 4 Various diseases with low cellular immune function. 5 Adjuvant treatment of tumors.

Indication: For chronic hepatitis B patients over 18 years old. Because the thymus begins to atrophy after 18 years old, the cellular immune function is reduced. 2 Various primary or secondary T cell deficiency diseases. 3 Certain autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.). 4 Various diseases with low cellular immune function. 5 Adjuvant treatment of tumors.